Rigel Pharmaceuticals, Inc. (RIGL)

NMS – Real Time Price. Currency in USD

29.37

+3.17 (12.10%)

At close: May 12, 2026, 4:00 PM EDT

29.68

+0.31 (1.06%)

Pre-market: May 13, 2026, 6:04 AM EDT

13.05.2026

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

12.05.2026

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).

12.05.2026

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC Pivotal Phase 3 VERITAC-2 clinical trial results showed that vepdegestrant was generally well tolerated and reported mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement, in patients with 2L+ ER+/HER2- mBC with an ESR1 mutation Upon closing of the transaction, VEPPANU will become Rigel's fourth commercial product and its major focus to accelerate revenue growth while leveraging the company's existing infrastructure, contributing meaningfully to the advancement of Rigel's transformational growth strategy Arvinas and Pfizer will receive an upfront $70.0 million and an additional $15.0 million upon the successful completion of certain transition activities, and are eligible for up to $320.0 million in future potential regulatory and commercial milestones Rigel to host a conference call today at 8:00 a.m.

06.05.2026

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

05.05.2026

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.63 per share a year ago.

05.05.2026

Rigel Reports First Quarter 2026 Financial Results

First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated $8.7 million of net income in the first quarter of 2026 On track to complete enrollment in the dose expansion phase of the Phase 1b study evaluating R289 and select the recommended Phase 2 dose in the second half of 2026 2026 Outlook: Total revenues of approximately $275 to $290 million, which includes net product sales of $255 to $265 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

29.04.2026

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

05.05.2026

Rigel Reports First Quarter 2026 Financial Results

07.04.2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

31.03.2026

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC SOUTH SAN FRANCISCO, Calif., March 31, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW study evaluating pralsetinib for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) in the Journal of Clinical Oncology.

Rigel Pharmaceuticals, Inc. (RIGL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel Reports First Quarter 2026 Financial Results

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Reports First Quarter 2026 Financial Results

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel Reports First Quarter 2026 Financial Results

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Reports First Quarter 2026 Financial Results

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Search stocks

Rigel Pharmaceuticals, Inc. (RIGL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel Reports First Quarter 2026 Financial Results

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Reports First Quarter 2026 Financial Results

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates

Rigel Reports First Quarter 2026 Financial Results

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Videos

No Data

Press releases

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

Rigel Reports First Quarter 2026 Financial Results

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology